SLC5A1 and metabolic dysfunction-associated steatohepatitis: ,98 Licogliflozin (LIK066), a chemical compound inhibiting both Sglt1 and Sglt2, was found to improve the liver function in obese patients with NASH in a phase 2 study (NCT03205150).99